<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/dosing.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="" ui-sref="DOSING" class="tab">DOSING</a>
        <a href="" ui-sref="DOSE-MODIFICATIONS" class="tab tab--active">DOSE MODIFICATIONS</a>
        <a href="" ui-sref="STORAGE-AND-HANDLING" class="tab">STORAGE & HANDLING</a>
    </div>

    <h2 class="primary">
        Modify BELEODAQ Treatment by Adjusting Dosage as Needed<sup>1</sup>
    </h2>
    <h3 class="secondary-variant">Modifying the dosage may allow for the possibility of continued treatment in some patients<sup>1</sup></h3>
    <div class="toxicity">
        <div class="toxicity__item">
            <h4 class="secondary-variant">Dosage modifications for hematologic toxicities<sup>1</sup></h4>
            <ul>
                <li>
                    <h4 class="light">
                    Base dosage adjustments for thrombocytopenia and neutropenia on the nadir (lowest value) for platelet and ANC in the preceding cycle of therapy
                </h4></li>
                <li>
                    <h4 class="light">
                    ANC should be ≥1,000/μL, and the platelet count should be ≥50,000/μL prior to the start of each cycle and prior to resuming treatment following discontinuation because of toxicity
                    <ul>
                        <li>Resume subsequent treatment with BELEODAQ according to the guidelines described in the table to the right</li>
                        <li>Discontinue BELEODAQ in patients who have recurrent ANC nadirs &lt;500/μL and/or recurrent platelet count nadirs &lt;25,000/μL after 2 dosage reductions</li>
                    </ul>
                </h4></li>
            </ul>
            <h4 class="secondary-variant">Preparation and administration precautions<sup>1</sup></h4>
            <ul>
                <li>
                    <h4 class="light">
                    As with other potentially cytotoxic anticancer agents, exercise care in the handling and preparation of solutions prepared with BELEODAQ</h4></li>
            </ul>
        </div>
        <div class="toxicity__item">
            <h4 class="secondary-variant center">Toxicity and dosage modification<sup>1</sup></h4>
            <div class="box darkest">
                <div class="box__header">
                <h4><span class="semibold">Platelet count</span> ≥ 25,000/μL and<br>
                    <span class="semibold">nadir ANC</span> ≥ 500/μL</h4>
                </div>
                <div class="box__content">
                    <h5>NO CHANGE</h5>
                </div>
            </div>
            <div class="box darker">
                <div class="box__header">
                <h4><span class="semibold">Nadir ANC</span> &lt; 500/μL<br>
                    (any platelet count)</h4>
                </div>
                <div class="box__content">
                    <h5>DECREASE DOSAGE BY
                        <span class="jumbo">25%</span>
                        <span class="light">(750 mg/m<sup>2</sup>)</span></h5>
                </div>
            </div>
            <div class="box">
                <div class="box__header">
                <h4><span class="semibold">Platelet count</span> &lt; 25,000/μL<br>
                    (any nadir ANC)</h4>
                </div>
                <div class="box__content">
                    <h5>DECREASE DOSAGE BY
                        <span class="jumbo">25%</span>
                        <span class="light">(750 mg/m<sup>2</sup>)</span></h5>
                </div>
            </div>
        </div>
    </div>

    <div class="modifications">
        <h4 class="light">
            Toxicities must be NCI-CTCAE grade 2 or less prior to retreatment
        </h4>
        <div class="mod-item">
            <h4 class="secondary-variant">
                Dosage modifications for nonhematologic toxicities<sup>1</sup>
            </h4>
            <div class="boxes">
                <div class="box">
                    <div class="box__header">
                        <h4 class="light">Any CTCAE 
                            grade 3 or 4 AE<sup>*</sup></h4>
                    </div>
                    <div class="box__content">
                        <h5>DECREASE DOSAGE BY
                            <span class="jumbo">25%</span>
                            <span class="light">(750 mg/m<sup>2</sup>)</span></h5>
                    </div>
                </div>
                <div class="box">
                    <div class="box__header">
                        <h4 class="light">Recurrence of CTCAE 
                            grade 3 or 4 AE 
                            after 2 dosage reductions </h4>
                    </div>
                    <div class="box__content">
                        <h5>DISCONTINUE
                            <span class="jumbo">BELEODAQ</span>
                            </h5>
                    </div>
                </div>
            </div>
            <p class="light"><sup>*</sup>For nausea, vomiting, and diarrhea, only dose modify if the duration is >7 days with supportive management.<sup>1</sup></p>
        </div>
    </div>

    <div class="bounding_box">
        <div class="bb_item">
            <h4 class="primary">Dosage modifications for patients with reduced <span class="italic">UGT1A1</span> activity<sup>1</sup>
            </h4>
            <div class="item__content">
                <img src="assets/svg/dosing/down-iv.svg" alt="Down Arrow with IV Bag" />
                <h4 class="light">Reduce the starting dose of BELEODAQ to <span class="primary semibold">750 mg/m<sup>2</sup></span> in patients known to be homozygous for the <span class="italic">UGT1A1*28</span> allele</h4>
            </div>
        </div>
        <div class="bb_item">
            <h4 class="secondary">
                Use in patients with renal impairment<sup>1</sup>
            </h4>
            <div class="item__content">
                <img src="assets/svg/dosing/kidney.svg" alt="Kidney Illustration" />
                <div>
                <h4 class="light">BELEODAQ exposure <span class="secondary semibold">is not altered in patients</span> with CrCl >39 mL/min
                    </h4>
                    <h4 class="light">
                    There are insufficient data to recommend a dose of BELEODAQ in patients with CrCl &#8804;39 mL/min
                    </h4>
                </div>
            </div>
        </div>
    </div>
    <h4 class="secondary-variant">Monitor complete blood counts at baseline and weekly<sup>1</sup><br>Perform serum chemistry tests, including renal and hepatic functions, prior to the start of the first dose of each cycle<sup>1</sup></h4>

    <p class="light">AE, adverse event; ANC, absolute neutrophil count; BSA, body surface area; CrCl, creatinine clearance; CTCAE, Common Terminology Criteria for Adverse Events; USP, US Pharmacopeia.</p>
    <div class="button-group">
        <a href="" ui-sref="SAFETY" class="button secondary"><i class="fas fa-chevron-left"></i> Safety & Tolerability</a>
        <a href="" ui-sref="ACCESS" class="button">Access & Resources <i class="fas fa-chevron-right"></i></a>
    </div>
</main>